ArticleJournal of medical biochemistry2025
Clinical application of butylphthalide sequential therapy on PTX-3, S100B, IL-6 in acute cerebral infarction.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute cerebral infarction (ACI) is a frequent type of stroke disease in clinical practice. Cognitive dysfunction is a common complication of ACI, which severely influences the quality of life of patients. Objective: To evaluate the effects of butylphthalide sequential therapy on inflammatory markers (PTX-3, S100B, IL-6) and cognitive outcomes in patients with acute cerebral infarction (ACI). Methods: From March 2023 to March 2024, 120 patients with ACI combined with cognitive dysfunction diagnosed and treated in our hospital were randomly divided into a control group (CG) and an observation group (OG). The clinical effective rate, MMSE scores, NIHSS scores, Barthel index scores, levels of inflammatory factors, and incidence of complications in both groups were compared. Results: Compared to the CG, the total effective rate of the OG was higher (c2=4.90, P<0.05). MMSE scores and Barthel index scores were elevated in both groups 2 weeks and 2 months after treatment, and those in the OG were higher relative to the CG (P<0.05). NIHSS scores and hs-CRP, as well as PTX-3 levels, declined in both groups 2 weeks and 2 months after treatment, and those in the OG were lessened compared to the CG (P<0.05). The occurrence of complications in the OG was reduced relative to the CG (P<0.05). Serum analysis showed lower hs-CRP, PTX-3, and IL-6 levels in the OG (P<0.05), suggesting reduced inflammation with butylphthalide therapy. While S100B levels showed a non-significant decline, albumin levels remained unchanged, indicating no significant impact on neuronal injury or nutritional recovery (P>0.05). Conclusions: Butylphthalide sequential therapy can promote the neurological function as well as living ability of patients with ACI combined with cognitive dysfunction, with high safety, which is valuable for clinical promotion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.